^
    5d
    SHARP: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • Viadur (leuprorelin implant)
    10d
    DUET study: DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. (2024-518985-29-02)
    P1/2, N=6, Completed, Amsterdam UMC Stichting | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 expression
    |
    Xofigo (radium Ra-223 dichloride)
    1m
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    IRST185.04: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (2024-511660-89-00)
    P1/2, N=70, Active, not recruiting, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • prednisone • Xofigo (radium Ra-223 dichloride)
    2ms
    COMRADE: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (clinicaltrials.gov)
    P1/2, N=145, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Mar 2025
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    CD4 (CD4 Molecule)
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    2ms
    BAT-RAD: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=47, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Xofigo (radium Ra-223 dichloride)
    2ms
    Remarkable Response to Etoposide and Cisplatin in Aggressive-Variant Prostate Cancer With Low Prostate-Specific Antigen Levels: A Case Report. (PubMed, Cureus)
    Subsequent radium-223 therapy further reduced bone metastases and normalized ALP levels, leading to substantial functional recovery. Furthermore, the favorable response to EP highlights the potential role of platinum-based chemotherapy in managing low-PSA, high-grade PC. Additional cases are needed to refine the clinical characterization of AVPC and establish evidence-based treatment guidelines.
    Journal
    |
    AR (Androgen receptor) • SYP (Synaptophysin) • NKX3-1 (NK3 homeobox 1)
    |
    cisplatin • etoposide IV • Xofigo (radium Ra-223 dichloride)
    3ms
    Low-Count Quantitative SPECT for Men Treated With Radium-223 (clinicaltrials.gov)
    P=N/A, N=38, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    3ms
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xofigo (radium Ra-223 dichloride)
    3ms
    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | N=54 --> 2 | Trial completion date: May 2028 --> Mar 2027 | Trial primary completion date: May 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    3ms
    DORA: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • Xofigo (radium Ra-223 dichloride)
    3ms
    In-situ ²²³Ra-doped calcium-alginate composite microspheres: a high-LET and immunoactivating platform for α-particle radioembolization in hepatocellular carcinoma. (PubMed, J Nanobiotechnology)
    Transcriptomics reveals activation of DNA-damage response, immunogenic cell death, and antigen-presentation pathways, flow cytometry and immunohistochemistry show increased dendritic-cell maturation and CD8⁺ T-cell infiltration. Collectively, 223Ra/Ca-ALG MS demonstrates hypoxia-tolerant cytotoxicity, immune-activating potential, offering new insights for the development of immune-based TARE strategies in HCC and showing promising prospects for clinical translation.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Xofigo (radium Ra-223 dichloride)